Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Anastasia Wyce"'
Autor:
Shane O’Brien, Michael Butticello, Christine Thompson, Boris Wilson, Anastasia Wyce, Vivek Mahajan, Ryan Kruger, Helai Mohammad, Andy Fedoriw
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Inhibitors of Poly (ADP-Ribose) Polymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising the DNA repair activity of cancer cells. Although these agents extend progression-free surviv
Externí odkaz:
https://doaj.org/article/02025abd74264dc0adf7fde4711f1a29
Autor:
Anastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, Chun-Wa Chung, Susan Korenchuk, Yuchen Bai, Olena Barbash, BaoChau Le, Peter D Craggs, Michael T McCabe, Karen M Kennedy-Wilson, Lydia V Sanchez, Romain L Gosmini, Nigel Parr, Charles F McHugh, Dashyant Dhanak, Rab K Prinjha, Kurt R Auger, Peter J Tummino
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72967 (2013)
BET family proteins are epigenetic regulators known to control expression of genes involved in cell growth and oncogenesis. Selective inhibitors of BET proteins exhibit potent anti-proliferative activity in a number of hematologic cancer models, in p
Externí odkaz:
https://doaj.org/article/edc29a7e49b54f8688b20ca3340035d5
Autor:
Michael Dickinson, Brandon E. Kremer, Arindam Dhar, Thierry Horner, Shawn W. Foley, Michael T. McCabe, Natalie O. Karpinich, Geraldine Ferron-Brady, Evi Bakirtzi, Olena Barbash, Anu Shilpa Krishnatry, Anastasia Wyce, Paolo Gallipoli, Ludovica Marando, Faisal Basheer, Regina García Delgado, Paul Yeh, Natalia Tovar, Maria-Victoria Mateos, Manali Kamdar, Jacob L. Glass, Gareth J. Morgan, Faith E. Davies, Daniel A. Pollyea, Dan T. Vogl, Aristeidis Chaidos, Adrian Alegre, Anastasios Karadimitris, Brian J.P. Huntly, Gautam Borthakur, Mark A. Dawson
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::634832d4a4352226ded7a6d727fa619e
https://doi.org/10.1158/1078-0432.22490779
https://doi.org/10.1158/1078-0432.22490779
Autor:
Michael Dickinson, Brandon E. Kremer, Arindam Dhar, Thierry Horner, Shawn W. Foley, Michael T. McCabe, Natalie O. Karpinich, Geraldine Ferron-Brady, Evi Bakirtzi, Olena Barbash, Anu Shilpa Krishnatry, Anastasia Wyce, Paolo Gallipoli, Ludovica Marando, Faisal Basheer, Regina García Delgado, Paul Yeh, Natalia Tovar, Maria-Victoria Mateos, Manali Kamdar, Jacob L. Glass, Gareth J. Morgan, Faith E. Davies, Daniel A. Pollyea, Dan T. Vogl, Aristeidis Chaidos, Adrian Alegre, Anastasios Karadimitris, Brian J.P. Huntly, Gautam Borthakur, Mark A. Dawson
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological maligna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b56a0a4932aa41df4a01b11e3217650
https://doi.org/10.1158/1078-0432.c.6533218.v1
https://doi.org/10.1158/1078-0432.c.6533218.v1
Autor:
Seock-Ah Im, Antoine Italiano, Jean-Yves Blay, Arun Azad, Victor Moreno, Christine L. Hann, Peter J. O'Dwyer, Matthew L. Hemming, Anastasia Wyce, Michael T. McCabe, Geoffrey I. Shapiro, Antara Datta, Thierry Horner, Philippe A. Cassier, Sarina Anne Piha-Paul, Sophie Cousin, Christophe Le Tourneau, Brandon E. Kremer, Ruth Plummer, Christopher A. French, Ahmed Khaled, Vicki L. Keedy, Jose Manuel Trigo, Johann S. de Bono, Yuehui Wu, Arindam Dhar, Geraldine Ferron-Brady, Marie-Paule Sablin, Shawn W. Foley, Irene Braña Garcia
Publikováno v:
International Journal of Cancer. 150:993-1006
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::580d9b3245154513254bc1a543a3a947
https://doi.org/10.1002/ijc.33861
https://doi.org/10.1002/ijc.33861
Autor:
Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria-Victoria Mateos, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological maligna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bebb86f092b88d6bc3976f8b349b6b15
https://pubmed.ncbi.nlm.nih.gov/36350312
https://pubmed.ncbi.nlm.nih.gov/36350312
Autor:
Alex Phillipou, Ryan G. Kruger, Simon Taylor, Chun-wa Chung, Rab K. Prinjha, Laurie J. Gordon, Robert J. Watson, James Gray, Alex Preston, James J. Foley, Cassie Messenger, Anna K. Bassil, Inmaculada Rioja, James Michael Woolven, Xi-Ping Zhang, Francesco Rianjongdee, Paola Grandi, Jeanne J. Matteo, Anastasia Wyce, Ian D. Wall, Paul Bamborough, Darren Jason Mitchell, Lee Andrew Harrison, Michael T. McCabe, Stephen John Atkinson, Jonathan Thomas Seal, Emmanuel Hubert Demont
Publikováno v:
Journal of medicinal chemistry. 64(15)
The profound efficacy of pan-BET inhibitors is well documented, but these epigenetic agents have shown pharmacology-driven toxicity in oncology clinical trials. The opportunity to identify inhibitors with an improved safety profile by selective targe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e26e07fd3767cf6b96980599351c38
https://pubmed.ncbi.nlm.nih.gov/34255512
https://pubmed.ncbi.nlm.nih.gov/34255512
Autor:
Sophie, Cousin, Jean-Yves, Blay, Irene Braña, Garcia, Johann S, de Bono, Christophe, Le Tourneau, Victor, Moreno, Jose, Trigo, Christine L, Hann, Arun A, Azad, Seock-Ah, Im, Philippe A, Cassier, Christopher A, French, Antoine, Italiano, Vicki L, Keedy, Ruth, Plummer, Marie-Paule, Sablin, Matthew L, Hemming, Geraldine, Ferron-Brady, Anastasia, Wyce, Ahmed, Khaled, Antara, Datta, Shawn W, Foley, Michael T, McCabe, Yuehui, Wu, Thierry, Horner, Brandon E, Kremer, Arindam, Dhar, Peter J, O'Dwyer, Geoffrey I, Shapiro, Sarina A, Piha-Paul
Publikováno v:
International journal of cancerREFERENCES. 150(6)
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::212a8358ef5d8574369dfa0f57022c31
https://pubmed.ncbi.nlm.nih.gov/34724226
https://pubmed.ncbi.nlm.nih.gov/34724226
Autor:
Jacob Ruden, Yimei Li, Jason R. Healy, Jo Lynne Rokita, Matthew Tsang, Jimmy Elias, Alexander L. Shazad, Lori S. Hart, John M. Maris, Maria Gagliardi, Robert W. Schnepp, Vandana Batra, Minu Samanta, Olena Barbash, Anastasia Wyce, Alvin Farrel
Publikováno v:
Pediatr Blood Cancer
Background The treatment of high-risk neuroblastoma continues to present a formidable challenge to pediatric oncology. Previous studies have shown that Bromodomain and extraterminal (BET) inhibitors can inhibit MYCN expression and suppress MYCN-ampli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e79aacee49a64ea88ccbb7b1dbee187f
https://doi.org/10.1002/pbc.28267
https://doi.org/10.1002/pbc.28267
Autor:
Angela Bridges, Sandrine Jayne, Jennifer Schofield, Ana Sousa Manso, Duncan S. Holmes, Xi-Ping Zhang, Larissa Lezina, Michael T. McCabe, Mark James Bamford, Anastasia Wyce, David Jonathan Hirst, Máire A. Convery, Tom Slocombe, Andrew C. Pearce, Don O. Somers, Simon D. Wagner, Paul Scott-Stevens, Ann Louise Walker, Jonathan P. Hutchinson, Constantinos Demetriou, Cassie Messenger, Melissa C. Musso, Sian Evans, Ruth C. Barber, Joanne Morley, Thomas Gobbetti
Publikováno v:
The Journal of Biological Chemistry
B-cell lymphoma 6 (BCL6) is a zinc finger transcriptional repressor possessing a BTB–POZ (BR-C, ttk, and bab for BTB; pox virus and zinc finger for POZ) domain, which is required for homodimerization and association with corepressors. BCL6 has mult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74c7e6fdf77eb69b9270c5b0a66260fc
https://doi.org/10.1016/j.jbc.2021.100928
https://doi.org/10.1016/j.jbc.2021.100928